Deutsches Eigenkapitalforum (EKF) 2023 healthcare


Deutsches Eigenkapitalforum (EKF) 2023 healthcare

Let us introduce you

The Deutsches Eigenkapitalforum (EKF) is one of the largest investor conferences in Europe, connecting European small and mid-caps, spanning several different sectors with an audience of global investors. We are proud to have been one of the event’s main sponsors since 2012.

We have written profiles on 26 companies that will be at EKF 2023 between 27 and 29 November, representing innovative businesses from across the consumer, financials, healthcare, industrials and technology sectors.

Each has a unique story to tell – of energy transition, of creating new medicines, of developing new technologies and much more.

And each has a story to tell of generating value.

If you would like to meet any of the 26 companies Edison is hosting at EKF, please contact us or register directly for Deutsches Eigenkapitalforum.

Click here for the sector book.

Check out the individual QuickView below:
Newron Pharmaceuticals

Written by:

Soo Romanoff

Soo Romanoff

Managing Director – Head of Content, Healthcare


Investment Companies | thematic

UK stock market – Scope for further upside in UK large-cap stocks

Investment Companies | thematic

Listed private equity – Performing a balancing act

Consumer | thematic

ConsumerWatch – At least someone loves me

TMT | thematic

MediaWatch – Rinse and repeat


VolitionRx – Decoding the DNA of cancer 

Curative therapies work best when administered early. Imagine therefore the benefits of a simple blood test that can detect cancer even before the first physical symptoms appear. Termed liquid biopsies, these tests have proved their mettle in disease monitoring and as companion diagnostics but their potential in early cancer screening remains to be unlocked. A possible roadblock is the need to enlist next-generation sequencing (NGS), to optimize sensitivity and specificity, which may make these tests, when positioned as mass-market diagnostics, too expensive, both for patients and payors. VolitionRx, a diagnostics company focused on epigenetics, is working on a solution that claims to physically isolate circulating tumor DNA (ctDNA) from background noise (no need for NGS), making for a convenient, fast and cost-effective test. Initial proof-of-concept data from a leukemia model have been encouraging, although significant clinical work is still required. Nevertheless, we see enough potential to warrant keeping an eye on the test’s development pathway.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free